Navigation Links
Recovery Act funds expand studies of stem cell biology
Date:10/28/2009

The National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health, is using $5.4 million of Recovery Act funds to accelerate basic studies of induced pluripotent stem cells. These cells, abbreviated iPS, are reprogrammed from skin or other easily obtained adult cells and appear to be similar to stem cells derived from embryos.

In theory, iPS cells could generate any type of cell and be used to treat diseases. But to realize this potential, scientists need a much better understanding of iPS cells' fundamental properties and how to efficiently derive cells that are safe for therapeutic uses.

To speed iPS research, NIGMS has awarded one-year grant supplements to 22 scientists at 16 institutions in 12 states and the District of Columbia. The investigators already have strong records of accomplishment in a range of research areas and will study iPS cells in varied biological systems.

"Stem cell biology is poised for rapid advances, and we expect our Recovery Act investment to have a catalytic effect. The new awards will contribute to the field's progress by enhancing the utility of iPS cells as tools for research, for testing the effects of drugs on human tissues and ultimately for patient-specific treatments," said NIGMS Director Jeremy M. Berg, Ph.D.

The Recovery Act funding will allow the scientists to address such important questions as:

  • How does reprogramming work?
  • What factors are necessary to create iPS cells efficiently and safely?
  • What drives iPS cells toward a desired cell type that can be used to regenerate or repair damaged tissues in a patient?
  • Do iPS cells differ from embryonic and adult stem cells, and if so, how?

The investigators receiving supplements are:

  • Bruce Beutler, Scripps Research Institute, La Jolla, Calif.
  • C. Anthony Blau, University of Washington, Seattle
  • Richard Cerione, Cornell University, Ithaca, N.Y.
  • Stephen Dalton, University of Georgia, Athens
  • Sharon Dent, University of Texas M.D. Anderson Cancer Center, Houston
  • Andres Garcia, Georgia Institute of Technology, Atlanta
  • David Gilbert, Florida State University, Tallahassee
  • Margaret Goodell, Baylor College of Medicine, Houston
  • Brenton Graveley, University of Connecticut Health Center, Farmington
  • Jeanne Lawrence, University of Massachusetts Medical School, Worcester
  • Jeannie Lee, Massachusetts General Hospital, Boston
  • Shaohua Li, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, Piscataway
  • John Lis, Cornell University, Ithaca, N.Y.
  • Nancy Maizels, University of Washington, Seattle
  • Sergie Nekhai, Howard University, Washington, D.C.
  • Sean Palecek, University of Wisconsin-Madison
  • Arnold Rizzino, University of Nebraska Medical Center, Omaha
  • Hannele Ruohola-Baker, University of Washington, Seattle
  • James Thomson, University of Wisconsin-Madison
  • Yi Wang, Baylor College of Medicine, Houston
  • Jeffrey Wilusz, Colorado State University, Fort Collins
  • Jerome Zack, University of California, Los Angeles


'/>"/>

Contact: Ann Dieffenbach
dieffena@nigms.nih.gov
301-496-7301
NIH/National Institute of General Medical Sciences
Source:Eurekalert  

Related biology news :

1. Survey finds elevated rates of new asthma among WTC rescue and recovery workers
2. New study shows greenback cutthroat trout involved in recovery effort misidentified
3. Recovery from acid rain much slower than expected
4. Diet and lifestyle critical to recovery, says study
5. Ozone hole recovery may reshape southern hemisphere climate change
6. Recovery efforts not enough for critically endangered Asian vulture
7. Diversity of plant-eating fishes may be key to recovery of coral reefs
8. Endangered sawfish focus of national collection and recovery efforts
9. Flowering plants speed post-surgery recovery
10. Long-term recovery of reefs from bleaching requires local action to increase resilience
11. Basic research critical to Americas economic recovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Recovery Act funds expand studies of stem cell biology
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
(Date:1/25/2017)... YORK , Jan. 25, 2017 The ... Access Management (IAM) lifecycle is comprised of a ... for the purpose of maintaining digital identities and ... resources and applications. There are significant number of ... from time to time by optimizing processes and ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... ... February 17, 2017 , ... The BMT Tandem Meetings of ... International Blood & Marrow Transplant Research (CIBMTR) will take place Feb. 22-26, 2017 ... combined scientific sessions offer investigators, clinicians, laboratory technicians, clinical research professionals, nurses, pharmacists, ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
(Date:2/16/2017)... Feb. 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage ... find a better treatment for triple negative breast cancer (TNBC), ... France program. The YEi Start ... designed to help entrepreneurs grow their business in ... eight American companies selected to complete an intensive one week ...
(Date:2/16/2017)... Feb. 16, 2017   Capricor Therapeutics, Inc. ... biotechnology company developing first-in-class biological therapies for cardiac ... has elected to terminate its license agreement with ... agonists, including Cenderitide. "Our decision to ... we prioritize our efforts to advance our core ...
Breaking Biology Technology: